ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced updated results from its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex including the 20 mg expansion cohort …
In a research report released Thursday, H.C.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shareholders woke up to a nice 10% pop in the value of their shares, after the drug maker announced the …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has indicating the firm will be shifting its R&D pipeline, centering its IL-12 gene therapy program on glioblastoma following …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company’s recent …
Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), particularly taking into account the seven clinical trials the firm has …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp (NYSE:XON) announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the third quarter ended September 30, 2016, and provided an update on the Company’s recent activities.
Griffin analyst Keith Markey was out pounding the table on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), reiterating a Buy rating and price target of $21.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company’s recent activities.